41 results about "Benserazide" patented technology

The invention discloses a levodopa / benserazide orally disintegrating tablet and a preparation method thereof. The tablet comprises the main drugs including levodopa and benserazide and the auxiliary materials including microcrystalline cellulose, mannitol, lactose, crospolyvinylpyrrolidone, low-substituted hydroxypropyl cellulose, sodium cyclamate, menthol, aerosol and magnesium stearate. The tablet of the invention can effectively treat the Parkinson disease or Parkinsonism syndrome, is convenient to take, good in mouthfeel, quick in disintegration, fast in absorption and high in bioavailability and provides convenience for the Parkinson disease or Parkinsonism syndrome patients who have difficulty in taking the whole tablet or feel inconvenient to take the tablet.

The invention discloses a levodopa / benserazide hydrochloride compound sustained-release suspension. The preparation contains by weight 10-50% of levodopa, 10-50% of benserazide hydrochloride and 10-50% of accessories. Compared with a solid preparation, the invention has the following advantages: the drug is coated in resin to improve drug stability; the preparation can be taken by doses to solve the problem that a large dose of drug prepared into an oral solid sustained release preparation is difficult to swallow; a multiple unit drug delivery system, in which drug release behavior is the sum of the drug release behavior of each particle, has better reproducibility and consistency; the preparation can avoid the situation of high local concentration caused by fragmentation of the oral solid sustained release preparation, and can cover the adverse taste of drugs and increase palatability. The sustained release preparation provided by invention can be used clinically as an anti-parkinsonian drug.

The invention relates to a levodopa methyl ester and benserazide mixed medicament slow-release microsphere composition. The composition comprises the following components in percentage by weight: 50 to 99 percent of degradable hydrophobic polymer and 1 to 50 percent of levodopa methyl ester and benserazide mixed medicament, wherein the weight ratio of the levodopa methyl ester to the benserazide is 1:1-4:1. The invention also provides a preparation method for the mixed medicament slow-release microsphere composition. The invention overcomes the disadvantage of unavailable effective treatment due to frequent missing of administration caused by the conventional single oral administration scheme and frequent oral administration requirement and provides a W / O / W preparation method. The particle diameter of the composition can be regulated and controlled from 1 to 500mu m according to different requirements without causing environmental pollution; the composition can prevent the influence on the treatment effect of the levodopa methyl ester and benserazide mixed medicament; the solution has the advantages of smooth and round surface, regularity and no adhesion; and the freeze-dried powder of the composition is white, fine, loose, non-collapse and non-adhesive and has high dispersibility.

Disclosed is a method for the treatment of a neurological or movement disorder, e.g., Parkinson's disease, in an individual in need thereof, by parenteral administration of levodopa and a dopa decarboxylase inhibitor (DDCI), such as carbidopa, benserazide or any combination thereof, concomitantly with oral administration of levodopa, a DDCI, such as carbidopa, benserazide, or any combination thereof.

The invention discloses the application of a compound pharmaceutical composition in the preparation of medicines for treating acute kidney injury. The compound pharmaceutical composition in the invention uses sarcogrelate and a 5-serotonin synthesis inhibitor as active ingredients, and the 5-serotonin synthesis inhibitor Carbidopa or benserazide. Sagrelate and carbidopa or benserazide can inhibit the synthesis of 5-HT 2 receptors and 5-HT in kidney cells, and have an obvious synergistic effect on the treatment of acute kidney injury, and have a significant effect on the treatment of acute kidney injury. Effect.

The invention relates to a benserazide sustained-release microspherical composition, which comprises the following components by weight percent: 40%-99% of a degradable hydrophobic polymer and 1%-60% of benserazide. The invention also provides a preparation method of the benserazide sustained-release microspherical composition. The invention can overcome the instability of benserazide during the storage process and improve the pharmaceutical therapeutic effect on patients. The method for preparing the microspherical composition can avoid the defects of low entrapment rate of the conventional W / O and W / O / W, and environmental pollution of S / O / O caused by serious burst release. In the invention, the grain diameter of the microspherical composition prepared by the method can be controlled according to different demands without environmental pollution, and the influence on the therapeutic effect of benserazide can be prevented. The surfaces of the obtained granules are smooth and rounded, the granules are regular without adhesion, the grain diameter can be regulated and controlled from 1mum to 5mum as required, and freeze-drying powder of the granules is white, exquisite and loose, is not collapsed and adhered, and has good redispersibility.

The present invention specifically relates to the use of BZE as an antibacterial agent. In view of the current situation that drug-resistant bacteria are increasing year by year, and the research and development cycle of antibacterial drugs is long, and the speed of marketing is slow, this field develops non-antibiotic drugs with antibacterial effects to deal with the difficult situation that drug-resistant bacteria are difficult to treat. Based on this technical idea, the present invention screens and verifies that BZE has a good antibacterial effect, and has a good in vitro complete inhibitory effect on MRSA, MDRAB and CRKP with high drug resistance. Based on the results of this study, BZE is expected to be developed as an active ingredient of a broad-spectrum antibacterial drug, which has good clinical and economic significance.

The invention relates to an application of a microsphere composition containing an antiparkinsonism drug to preparation of a medicine for preventing and treating parkinson diseases and complicating diseases of parkinson diseases. The microsphere composition containing the antiparkinsonism drug is selected from benserazide microspheres, L-dopa methyl ester microspheres, the L-dopa methyl ester microspheres and the benserazide microspheres, or L-dopa methyl ester and benserazide mixing drug microspheres. The invention also provides a microsphere combination medicament containing the antiparkinsonism drug. The invention explores novel medical application for the microsphere combination medicament containing the antiparkinsonism drug and develops a novel application field. The microsphere combination medicament containing the antiparkinsonism drug of the invention is safe and nontoxic, has strong pharmacological action and indicates good medicinal prospect.

Disclosed is a method for the treatment of a neurological or movement disorder, e.g., Parkinson's disease, in an individual in need thereof, by parenteral administration of levodopa and a dopa decarboxylase inhibitor (DDCI), such as carbidopa, benserazide or any combination thereof, concomitantly with oral administration of levodopa, a DDCI, such as carbidopa, benserazide, or any combination thereof.